Interleukin-6-knockdown of chimeric antigen receptor-modified T cells significantly reduces IL-6 release from monocytes

Interleukin-6-knockdown of chimeric antigen receptor-modified T cells significantly reduces IL-6 release from monocytes

Abstract Background T cells expressing a chimeric antigen receptor (CAR) engineered to target CD19 can treat leukemia effectively but also increase the risk of complications such as cytokine release syndrome (CRS) and CAR T cell related encephalopathy (CRES) driven by interleukin-6 (IL-6). Here, we...

Full description

Bibliographic Details
Main Authors: Liqing Kang, Xiaowen Tang, Jian Zhang, Minghao Li, Nan Xu, Wei Qi, Jingwen Tan, Xiaoyan Lou, Zhou Yu, Juanjuan Sun, Zhenkun Wang, Haiping Dai, Jia Chen, Guoqing Lin, Depei Wu, Lei Yu
Format: Article
Language:English
Published: BMC 2020-06-01
Series:Experimental Hematology & Oncology
Subjects:
CAR-T
CRS
CRES
IL-6
shRNA
safety
Online Access:http://link.springer.com/article/10.1186/s40164-020-00166-2

Similar Items

Similar Items